Prospective population-based studies, which have been used to provide gold-standard estimates of lifetime cancer risk in BRCA1, BRCA2, and the mismatch repair genes, would provide more accurate risk estimates for moderate penetrance ovarian cancer genes, but are costly, and require long-term investment. The gene discussed is BRCA1; the disease is ovarian carcinoma.